Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29586142 | 1.00 | USP7 (1.00) | USP7 | |
| SCHEMBL18066747 | 0.96 | USP7 (0.93) | USP7 | |
| SCHEMBL29586192 | 0.96 | USP7 (0.93) | USP7 | |
| SCHEMBL29587605 | 0.81 | USP7 (0.68) | USP7 | |
| SCHEMBL18066739 | 0.81 | USP7 (0.68) | USP7 | |
| SCHEMBL29586183 | 0.79 | USP7 (0.72) | USP7 | |
| SCHEMBL18066768 | 0.79 | USP7 (0.72) | USP7 | |
| SCHEMBL18066809 | 0.78 | USP7 (1.00) | USP7 | |
| SCHEMBL29586173 | 0.78 | USP7 (1.00) | USP7 | |
| SCHEMBL18066794 | 0.78 | USP7 (1.00) | USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271333-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2018-01-24 | — | — | EP | claimed |
| US-9573899-B2 | USP7 inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | claimed |
| WO-2016150800-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-29 | — | — | WO | claimed |
| US-20160272588-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-09-22 | — | — | US | claimed |
| CN-107531683-B | USP7 inhibitor compounds and methods of use | 豪夫迈·罗氏有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3271333-B1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2022-01-12 | — | — | EP | disclosed |
| EP-3271333-B1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2022-01-12 | — | — | EP | disclosed |
| EP-3271333-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| US-9573899-B2 | USP7 inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573899-B2 | USP7 inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573899-B2 | USP7 inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2016150800-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-29 | — | — | WO | disclosed |
| US-20160272588-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272588-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272588-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272588-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | USP7, UBA7, USP1 | USP7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.